NEW YORK (GenomeWeb) – A team led by Johns Hopkins Kimmel Cancer Center researchers has developed a model that uses routine pathologic parameters to identify breast cancer patients for whom molecular-based recurrence testing with Oncotype DX is likely to provide added information.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.